184 related articles for article (PubMed ID: 38604929)
1. Exploiting pancreatic cancer metabolism: challenges and opportunities.
De Santis MC; Bockorny B; Hirsch E; Cappello P; Martini M
Trends Mol Med; 2024 Apr; ():. PubMed ID: 38604929
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Cohen R; Neuzillet C; Tijeras-Raballand A; Faivre S; de Gramont A; Raymond E
Oncotarget; 2015 Jul; 6(19):16832-47. PubMed ID: 26164081
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities.
Bogut A; Stojanovic B; Jovanovic M; Dimitrijevic Stojanovic M; Gajovic N; Stojanovic BS; Balovic G; Jovanovic M; Lazovic A; Mirovic M; Jurisevic M; Jovanovic I; Mladenovic V
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958483
[TBL] [Abstract][Full Text] [Related]
4. Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors.
Reyes-Castellanos G; Abdel Hadi N; Carrier A
Cells; 2022 Jan; 11(3):. PubMed ID: 35159234
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment.
Yamamoto K; Iwadate D; Kato H; Nakai Y; Tateishi K; Fujishiro M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139512
[TBL] [Abstract][Full Text] [Related]
7. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
8. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies.
Xu R; Yang J; Ren B; Wang H; Yang G; Chen Y; You L; Zhao Y
Front Oncol; 2020; 10():572722. PubMed ID: 33117704
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges.
Poh AR; Ernst M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201127
[TBL] [Abstract][Full Text] [Related]
11. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.
Andersen HB; Ialchina R; Pedersen SF; Czaplinska D
Cancer Metastasis Rev; 2021 Dec; 40(4):1093-1114. PubMed ID: 34855109
[TBL] [Abstract][Full Text] [Related]
12. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy as a therapeutic strategy against pancreatic cancer.
Yamamoto K; Iwadate D; Kato H; Nakai Y; Tateishi K; Fujishiro M
J Gastroenterol; 2022 Sep; 57(9):603-618. PubMed ID: 35727403
[TBL] [Abstract][Full Text] [Related]
14. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Recouvreux MV; Grenier SF; Zhang Y; Esparza E; Lambies G; Galapate CM; Maganti S; Duong-Polk K; Bhullar D; Naeem R; Scott DA; Lowy AM; Tiriac H; Commisso C
Nat Cancer; 2024 Jan; 5(1):100-113. PubMed ID: 37814011
[TBL] [Abstract][Full Text] [Related]
15. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.
Palma AM; Vudatha V; Peixoto ML; Madan E
Adv Cancer Res; 2023; 159():203-249. PubMed ID: 37268397
[TBL] [Abstract][Full Text] [Related]
16. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
17. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy.
Zhang H; Xu W; Zhu H; Chen X; Tsai HI
J Cancer; 2024; 15(7):2003-2023. PubMed ID: 38434964
[TBL] [Abstract][Full Text] [Related]
19. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
20. Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma.
Rai V; Agrawal S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
